Therapeutic index

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch. The therapeutic index (also known as therapeutic ratio), is a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes toxic effects. Quantitatively, it is the ratio given by the dose required to produce the toxic effect divided by the therapeutic dose. A commonly used measure of therapeutic index is the lethal dose of a drug for 50% of the population (LD₅₀) divided by the minimum effective dose for 50% of the population (ED₅₀).

Generally, a drug with a narrow therapeutic range (i.e. with little difference between toxic and therapeutic doses) may have its dosage adjusted according to measurements of the actual blood levels achieved in the person taking it. This may be achieved through therapeutic drug monitoring (TDM) protocols. Examples of drugs with a narrow therapeutic range, that may require drug monitoring both to achieve therapeutic levels and minimise toxicity, include: digoxin, dimercaprol, theophylline, and lithium carbonate. Some antibiotics require monitoring primarily to minimise adverse effects, including: gentamicin, vancomycin, amphotericin B, and polymyxin B.

An important related factor is the leverage of targeting. For example, shaping radiation beams precisely to the profile of a tumor in the "beam's eye view" can increase the delivered dose without increasing toxic effects, though such shaping might not change the therapeutic index. Similarly, when chemotherapy or radiotherapy is infused or injected, the delivery ratio can be much higher when the chemotherapy agent or radioisotope is attached to an oncophilic substance — as is done in peptide receptor radionuclide therapy for neuroendocrine tumors and in chemoembolization or radioactive microspheres therapy for liver tumors and metastases — again, that might not change the therapeutic index.

See also

• Effective dose
• IC₅₀
• LD₅₀
• EC₅₀
• Certain safety factor

de:Therapeutische Breite he:חלון תרפויטי nl:Therapeutische breedte sl:Terapevtski indeks